SRC and head and neck squamous cell carcinoma: In summary, we unveil that the insufficient suppression of the AKT-S6 signaling axis is one of the mechanisms associated with decrease clinical benefits of Src-targeted treatment in HNSCC patients, and co-inhibition of Src and AKT represents a compelling strategy for achieving superior anti-HNSCC effects in those patients harboring these activations.